Karus is a research and development focused pharmaceutical company that is developing a new family of small-molecule drugs for the treatment of chronic human diseases such as cancer and inflammation.
The company's focus is the development of a new family of optimized, highly-potent and highly-selective histone deacetylase (HDAC) inhibitors (HDI's) which the company believes have the potential to become best-in-class treatments for cancer and inflammation.
Karus sits at the interface of innovative medicinal chemistry and unique insights in cancer-cell biology creating opportunities to design, optimize and develop new medicines.
Karus has established a strong and multi-disciplinary commercial and scientific team that is enabling the company to make rapid progress towards the clinic. The Company's lead programme is a synthetically optimised derivative of a clinically validated natural product with significantly improved potency, safety and dry-like properties.
Karus's unique approach to drug design has created new families of therapeutics that have blockbuster potential in major diseases such as cancer, inflammation and cardiovascular disease.
Simon Kerry, Chief Executive Officer
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom